Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2026-05-14 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于控股股东权益变动触及1%刻度的提示性公告
Major Shareholding Notification Classification · 90% confidence The document is a formal disclosure by KunYao Group (证券代码：600422) about a change in the shareholding percentage of its controlling shareholder China Resources Sanjiu Medical Co., Ltd. The controlling shareholder increased its stake from 28.05% to 29.01%, triggering the 1% threshold disclosure requirement under Shanghai Stock Exchange rules. This fits the precise definition of a "Major Shareholding Notification" which covers notifications of changes in significant share ownership levels crossing regulatory thresholds. Therefore, the appropriate classification is MRQ.
2026-05-14 Chinese
昆药集团关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Kunming Pharmaceutical Group Co., Ltd. It references a new accounting standard interpretation issued by the Ministry of Finance of China and explains the nature and impact of the change. The document is relatively short (1012 characters) and does not contain any financial statements or detailed financial data. It is a formal disclosure about accounting policy changes rather than a full financial report or audit report. It does not fit categories like Annual Report, Interim Report, or Audit Report. It is also not a report publication announcement since it contains substantive content about the policy change itself. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-04-24 Chinese
昆药集团十一届十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It reports on the decisions made at the company's 18th meeting of the 11th board, including approval of the 2026 Q1 report and election of a new vice chairman of the board. The document contains voting results and details about the board meeting but does not include the actual quarterly financial report or detailed financial data. It is an announcement of board/management changes and resolutions rather than a full financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, not the report itself.
2026-04-24 Chinese
昆药集团关于部分董事及高级管理人员变更的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's board of directors and senior management personnel. It details resignations and appointments of directors and executives, including their roles, reasons for leaving, and new appointments. There is no financial data, earnings information, or report publication mentioned. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board or senior management.
2026-04-24 Chinese
昆药集团2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "昆药集团股份有限公司2026年第一季度报告" which translates to "Kunming Pharmaceutical Group Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management discussion of business conditions for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending March 31, 2026. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-24 Chinese
昆药集团关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a performance explanation meeting (业绩说明会) for the 2025 annual results and 2026 first quarter results. It mentions the meeting time, location, participation method, and that company executives will answer investor questions. It references that the 2025 annual report and 2026 Q1 report have already been published, but this document itself is not the report or the transcript of the meeting. It is a notice about the upcoming earnings call or performance explanation meeting. This fits the definition of a Call Transcript (CT) type document, as it is a performance explanation meeting announcement with interactive Q&A. However, since it is only an announcement of the meeting and not the transcript itself, it is not a CT. It is also not a Regulatory Filing (RNS) because it is a formal announcement of a scheduled event. The best fitting category is Investor Presentation (IP) because the document is a detailed presentation for investors focusing on financial results and interaction, even though it is an announcement of the meeting rather than the presentation slides. The document length is short (1389 characters), but it contains detailed information about the meeting and investor interaction, which aligns with IP rather than RPA or RNS. Therefore, the classification is IP with high confidence.
2026-04-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.